Safety,Tolerability and Pharmacokinetics of Doravirine,a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor,after Single and Multiple doses in Healthy Subjects
Free accessResearch articleFirst published online May, 2015
Safety,Tolerability and Pharmacokinetics of Doravirine,a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor,after Single and Multiple doses in Healthy Subjects
Doravirine is a novel non-nucleoside inhibitor of HIV-1 reverse transcriptase with potent activity against wild-type virus (95% inhibitory concentration 19 nM, 50% human serum). Doravirine has low potential to cause drug–drug interactions since it is primarily eliminated by oxidative metabolism and does not inhibit or significantly induce drug-metabolizing enzymes.
Methods
The pharmacokinetics and safety of doravirine were investigated in two double-blind, dose-escalation studies in healthy males. Thirty-two subjects received single doses of doravirine (6–1,200 mg) or matching placebo tablets; 40 subjects received doravirine (30–750 mg) or matching placebo tablets once daily for 10 days. In addition, the effect of doravirine (120 mg for 14 days) on single-dose pharmacokinetics of the CYP3A substrate midazolam was evaluated (10 subjects).
Results
The maximum plasma concentration (Cmax) of doravirine was achieved within 1–5 h with an apparent terminal half-life of 12–21 h. Consistent with single-dose pharma-cokinetics, steady state was achieved after approximately 7 days of once daily administration, with accumulation ratios (day 10/day 1) of 1.1–1.5 in the area under the plasma concentration–time curve during the dosing interval (AUC0–24h), Cmax and trough plasma concentration (C24h). All dose levels produced C24h>19 nM. Administration of 50 mg doravirine with a high-fat meal was associated with slight elevations in AUC time zero to infinity (AUC0–∞) and C24h with no change in Cmax. Midazolam AUC0–∞ was slightly reduced by coadministration of doravirine (geometric mean ratio 0.82, 90% CI 0.70, 0.97). There was no apparent relationship between adverse event frequency or intensity and doravirine dose. No rash or significant central nervous system events other than headache were reported.
Conclusions
Doravirine is generally well tolerated in single doses up to 1,200 mg and multiple doses up to 750 mg once daily for up to 10 days, with a pharmacokinetic profile supportive of once-daily dosing. Doravirine at steady state slightly reduced the exposure of coadministered midazolam, to a clinically unimportant extent.
References
1.
de BéthuneM.P.Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009).Antiviral Res2010; 85: 75–90.
2.
LaiM.T.Antiviral activity and in vitro mutation development pathways of MK-1439: a novel non-nucleoside reverse transcriptase inhibitor (NNRTI).Interscience Conferenceon Antimicrobial Agents & Chemotherapy (ICAAC). 9–12 September 2012, San Francisco, CA, USA. Abstract H551.
3.
VaccaJ.P., DorseyB.D., SchleifW.A.L-735,524: an orally bioavailable human immuno-deficiency virus type 1 protease inhibitor.Proc Natl Acad Sci U S A1994; 91: 4096–4100.
4.
BilelloJ.A., BauerG., DudleyM.N., ColeG.A., DrusanoG.L.Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies.Antimicrob Agents Chemother1994; 38: 1386–1391.
5.
DrusanoG.L., MooreK.H., KleimJ.P., PrinceW., ByeA.Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation.Antimicrob Agents Chemother2002; 46: 913–916.
6.
Morales-RamirezJ.O., GatellJ.M., HaginsD.P.Safety & antiviral effect of MK-1439, a novel NNRTI, (+TDF/ FTC) in ART-naive HIV infected patients.Conference on Retroviruses and Opportunistic Infections (CROI). 3–6 March 2014, Boston, MA, USA. Abstract 92LB.
